ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 11

PMID 38201581

Authors

Andrea Duminuco

Helen T Chifotides

Sebastiano Giallongo

Cesarina Giallongo

Daniele Tibullo

Giuseppe A Palumbo

Affiliations

Soon will be listed here.

Abstract

Activin receptor type I (ACVR1) is a transmembrane kinase receptor belonging to bone morphogenic protein receptors (BMPs). ACVR1 plays an important role in hematopoiesis and anemia via the BMP6/ACVR1/SMAD pathway, which regulates expression of hepcidin, the master regulator of iron homeostasis. Elevated hepcidin levels are inversely associated with plasma iron levels, and chronic hepcidin expression leads to iron-restricted anemia. Anemia is one of the hallmarks of myelofibrosis (MF), a bone marrow (BM) malignancy characterized by BM scarring resulting in impaired hematopoiesis, splenomegaly, and systemic symptoms. Anemia and red blood cell transfusions negatively impact MF prognosis. Among the approved JAK inhibitors (ruxolitinib, fedratinib, momelotinib, and pacritinib) for MF, momelotinib and pacritinib are preferably used in cytopenic patients; both agents are potent ACVR1 inhibitors that suppress hepcidin expression via the BMP6/ACVR1/SMAD pathway and restore iron homeostasis/erythropoiesis. In September 2023, momelotinib was approved as a treatment for patients with MF and anemia. Zilurgisertib (ACVR1 inhibitor) and DISC-0974 (anti-hemojuvelin monoclonal antibody) are evaluated in early phase clinical trials in patients with MF and anemia. Luspatercept (ACVR2B ligand trap) is assessed in transfusion-dependent MF patients in a registrational phase 3 trial. Approved ACVR1 inhibitors and novel agents in development are poised to improve the outcomes of anemic MF patients.

Citing Articles

Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.

Duminuco A, Bulla A, Rosso R, Romeo M, Cambria D, La Spina E Vaccines (Basel). 2025; 13(2).

PMID: 40006658 PMC: 11860232. DOI: 10.3390/vaccines13020111.

Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis.

Spampinato M, Giallongo C, Giallongo S, La Spina E, Duminuco A, Longhitano L J Transl Med. 2025; 23(1):69.

PMID: 39810250 PMC: 11734442. DOI: 10.1186/s12967-025-06083-4.

Emergencies in Hematology: Why, When and How I Treat?.

Duminuco A, Del Fabro V, De Luca P, Leotta D, Limoli M, Longo E J Clin Med. 2025; 13(24.

PMID: 39768494 PMC: 11728391. DOI: 10.3390/jcm13247572.

Investigational drugs in early phase trials for myelofibrosis.

Arora S, Vachhani P, Bose P Expert Opin Investig Drugs. 2024; 33(12):1231-1244.

PMID: 39604120 PMC: 11669310. DOI: 10.1080/13543784.2024.2434696.

Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology.

Jimmidi R, Monsivais D, Ta H, Sharma K, Bohren K, Chamakuri S Proc Natl Acad Sci U S A. 2024; 121(47):e2413108121.

PMID: 39541346 PMC: 11588046. DOI: 10.1073/pnas.2413108121.

References

Verstovsek S, Kiladjian J, Vannucchi A, Mesa R, Squier P, Hamer-Maansson J . Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer. 2023; 129(11):1681-1690. DOI: 10.1002/cncr.34707. View

Verstovsek S, Gotlib J, Mesa R, Vannucchi A, Kiladjian J, Cervantes F . Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017; 10(1):156. PMC: 5622445. DOI: 10.1186/s13045-017-0527-7. View

Palumbo G, Cambria D, La Spina E, Duminuco A, Laneri A, Longo A . Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. Front Oncol. 2023; 13:1117815. PMC: 9974162. DOI: 10.3389/fonc.2023.1117815. View

Valore E, Ganz T . Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2007; 40(1):132-8. PMC: 2211381. DOI: 10.1016/j.bcmd.2007.07.009. View

Harrison C, Garcia J, Somervaille T, Foran J, Verstovsek S, Jamieson C . Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022; 40(15):1671-1680. PMC: 9113204. DOI: 10.1200/JCO.21.02188. View

Chifotides H, Bose P, Verstovsek S . Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022; 15(1):7. PMC: 8772195. DOI: 10.1186/s13045-021-01157-4. View

Verstovsek S, Al-Ali H, Mascarenhas J, Perkins A, Vannucchi A, Mohan S . BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future Oncol. 2022; . DOI: 10.2217/fon-2022-0901. View

Oh S, Mesa R, Harrison C, Bose P, Gerds A, Gupta V . Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023; 7(19):5835-5842. PMC: 10561048. DOI: 10.1182/bloodadvances.2023010151. View

Longhitano L, Tibullo D, Vicario N, Giallongo C, La Spina E, Romano A . IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis. Aging (Albany NY). 2021; 13(23):25055-25071. PMC: 8714138. DOI: 10.18632/aging.203779. View

10.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

11.

Barruet E, Morales B, Lwin W, White M, Theodoris C, Kim H . The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Stem Cell Res Ther. 2016; 7(1):115. PMC: 4988052. DOI: 10.1186/s13287-016-0372-6. View

12.

Carreau N, Tremblay D, Savona M, Kremyanskaya M, Mascarenhas J . Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes. Blood Rev. 2016; 30(5):349-56. DOI: 10.1016/j.blre.2016.04.003. View

13.

Feng X, Derynck R . Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005; 21:659-93. DOI: 10.1146/annurev.cellbio.21.022404.142018. View

14.

Mascarenhas J, Harrison C, Schuler T, Liassou D, Garretson M, Miller T . Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. Clin Lymphoma Myeloma Leuk. 2023; 24(2):122-132. DOI: 10.1016/j.clml.2023.09.008. View

15.

Duminuco A, Nardo A, Garibaldi B, Vetro C, Longo A, Giallongo C . Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting. J Clin Med. 2022; 11(24). PMC: 9783796. DOI: 10.3390/jcm11247418. View

16.

Shahid M, Spagnolli E, Ernande L, Thoonen R, Kolodziej S, Leyton P . BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2016; 310(8):H984-94. PMC: 4867336. DOI: 10.1152/ajpheart.00879.2015. View

17.

Harrison C, Vannucchi A, Kiladjian J, Al-Ali H, Gisslinger H, Knoops L . Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8):1701-7. PMC: 5399157. DOI: 10.1038/leu.2016.148. View

18.

Elli E, Iurlo A, Aroldi A, Caramella M, Malato S, Casartelli E . Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study). Br J Haematol. 2019; 186(5):e123-e126. DOI: 10.1111/bjh.15964. View

19.

Pasca S, Chifotides H, Verstovsek S, Bose P . Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124. DOI: 10.1016/bs.ircmb.2021.02.008. View

20.

Harrison C, Vannucchi A, Platzbecker U, Cervantes F, Gupta V, Lavie D . Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017; 5(2):e73-e81. DOI: 10.1016/S2352-3026(17)30237-5. View